Clinical Trial Results:
A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib versus Placebo in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated with Docetaxel in the 2nd/3rd Line Setting (PRESERVE 4)
Summary
|
|
EudraCT number |
2021-000186-32 |
Trial protocol |
ES PL IT |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1 |
This version publication date |
14 Nov 2022
|
First version publication date |
14 Nov 2022
|
Other versions |
v2 |
Summary report(s) |
G1T28-210: A PHASE 2 RANDOMIZED, DOUBLE-BLIND, CLINICAL TRIAL OF TRILACICLIB VERSUS PLACEBO IN PATIENTS WITH METASTATIC NSCLC TREATED WITH DOCETAXEL IN THE 2ND/3RD LINE SETTING (PRESERVE 4) |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.